share_log

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

ocugen将于11月8日星期五上午8:30举行电话会议,讨论业务更新和2024年第三季度财务业绩
Ocugen ·  10/17 00:00

MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's third quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Friday, November 8, 2024.

MALVERN,宾夕法尼亚州,2024年10月17日(NASDAQ: OCGN)本次贝塔会议-半导体交易所生物技术公司正在致力于发现、开发和商业化新型基因和电芯疗法、生物制品和疫苗,今天宣布将于2024年11月8日星期五上午8:30 Et举行一个电话会议和现场网络直播,讨论公司2024年第三季度财务业绩并提供业务更新。

Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:

Ocugen将在同一天发表市前收益声明。与会者可使用以下细节参加会议:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 9923172
Webcast: Available on the events section of the Ocugen investor site

美国参与者拨打电话号码:(800)715-9871,国际参与者拨打电话号码:(646)307-1963
会议标识: 9923172
网络研讨会:在ocugen投资者网站的事件部分提供

A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site.

在ocugen投资者网站上,呼叫和已存档的网络研讨会将在事件之后的约45天内提供。

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at and follow us on X and LinkedIn.

Ocugen是一家生物技术公司,致力于发现,开发和商业化新型基因和细胞疗法以及疫苗,以改善全球患者的健康并为他们带来希望。我们通过勇敢的创新影响着患者的生活,开拓了新的科学路径,利用我们独特的智力和人力资本。我们的突破性调节基因治疗平台具有使用单一产品治疗多种视网膜疾病的潜力,并且我们正在推进传染病的研究,以支持公共卫生和改善骨科疾病,以满足医疗领域的未满足需求。访问更多信息,请浏览网站,并在X和LinkedIn上关注我们。
ocugen是一家专注于发现、开发和商业化新基因和电芯疗法、生物制品和疫苗的生物技术公司,旨在改善全球患者的健康状况并为他们带来希望。我们通过勇敢的创新对患者的生活产生影响,开创了利用独特智力和人力资源的新科学路径。我们的突破性调节基因疗法平台有潜力用单一产品治疗多种视网膜疾病,我们正在推动感染病研究以支持公共卫生和骨科疾病研究以满足医疗需求的空白。在 上了解更多信息,并在 X 和 LinkedIn 关注我们。

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

前瞻性声明的警示说明
本新闻稿包含根据1995年《私人证券诉讼改革法案》的涉及风险和不确定性的前瞻性声明。我们在某些情况下使用诸如“预测”、“相信”、“潜力”、“提出”、“继续”、“估计”、“预计”、“计划”、“打算”、“可能”、“可能”、“将”、“应该”或其他表示对未来事件或结果的不确定性的词语,以确定这些前瞻性声明。这些声明受到许多重要因素、风险和不确定性的影响,可能导致实际事件或结果与我们目前的预期大不相同。这些和其他风险和不确定性在我们向证券交易委员会(SEC)提交的定期文件中得到更全面的描述,包括在我们向SEC提交的季度和年度报告中所述的风险因素部分。我们在本新闻稿中做出的任何前瞻性声明仅适用于本新闻稿发表日。除非法律要求,否则我们不承担更新本新闻稿中包含的前瞻性声明的义务,无论是因为获取新信息、未来事件或其他原因,都不承担义务,也不对其进行更新。

Contact:
联系方式:

Tiffany Hamilton
蒂芙尼·汉密尔顿

Head of Communications
通信主管

Tiffany.Hamilton@ocugen.com
Tiffany.Hamilton@ocugen.com

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发